Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AbbVie (ABBV) meets the primary goal in the phase II study evaluating Rinvoq in the treatment of adult patients with non-segmental vitiligo.

AbbVie's (ABBV) Rinvoq Meets Key Goal in Phase II Vitiligo Study

Paul Tudor Jones told CNBC this week that the bond market could push interest rates higher and cause a recession. He believes that the stock market will fall quite a bit before this predicted recession begins.

Billionaire Paul Tudor Jones Predicts a Recession in Early 2024. Here's What It Could Mean for Stocks.

At week 24, upadacitinib met the primary endpoint of percent change from baseline in Facial Vitiligo Area Scoring Index (F-VASI) with 11 mg and 22 mg doses versus placebo in adults with non-segmental vitiligo (NSV)1 At week 52, the percent reduction from baseline in F-VASI was numerically greater than results at week 24 for all upadacitinib doses1,2 The safety profile was consistent with the known safety profile for upadacitinib1,2 NORTH CHICAGO, Ill. , Oct. 11, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that its Phase 2b study evaluating upadacitinib (RINVOQ®) in adults with non-segmental vitiligo (NSV) met the primary endpoint of percent change from baseline in the Facial Vitiligo Area Scoring Index (F-VASI) at week 24 with the 11 mg and 22 mg doses versus placebo.1 The percent reduction from baseline in F-VASI at week 52 was numerically greater than results at week 24 for all upadacitinib doses.2 No new safety signals were identified beyond the known safety profile for upadacitinib.

AbbVie Announces Upadacitinib (RINVOQ®) Met the Primary Endpoint in Phase 2 Clinical Trial of Vitiligo as Program Advances to Phase 3

Three ongoing, randomized, double-blind, multicenter Phase 3 studies demonstrated the long-term efficacy and safety profile of RINVOQ® (upadacitinib) in treating moderate to severe atopic dermatitis based on results across 140 weeks1 Response rates for EASI 75 and vIGA-AD 0/1 (co-primary endpoints) and for EASI 90 and WP-NRS 0/1 at week 16 were sustained through week 140 among patients treated with RINVOQ1 Safety results were consistent with the known safety profile of upadacitinib, with no new safety signals observed1 Data will be presented as an oral presentation at the 32nd European Academy of Dermatology and Venereology (EADV) Congress NORTH CHICAGO, Ill. , Oct. 11, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new data analyses from the Measure Up 1, Measure Up 2 and AD Up Phase 3 studies that further demonstrated the long-term efficacy and safety profile of RINVOQ® (upadacitinib) among adults and adolescents 12 years and older with moderate to severe atopic dermatitis through 140 weeks.

AbbVie Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ (upadacitinib) in Adults and Adolescents with Moderate to Severe Atopic Dermatitis

Cisco Systems

Verizon

Verizon Communications, Cisco Systems, and AbbVie are all high-yielding dividend stocks that provide good value. These stocks are all cheap buys, trading at low future earnings multiples.

3 Absurdly Cheap Dividend Stocks to Buy and Hold for Years

Walmart

Nervous investors are turning to defensive stocks, and there's plenty of reason to be among their ranks. The U.S. Federal Reserve's continuing battle to control inflation is the primary reason catalyzing increasing nervousness.

The 3 Best Defensive Stocks for Nervous Investors

Colgate-Palmolive

Dividend stocks have proved time and again to be a superior investing strategy. We all want capital appreciation, or to see our stocks grow in value over time, but dividends are what really drive excess returns.

3 Dividend Kings Every Investor Should Own to Survive a Market Crash

–   Late-breaking data from a head-to-head study evaluating SKYRIZI® (risankizumab) versus STELARA® (ustekinumab) in moderate to severe Crohn's disease will be presented –   Analyses on clinical and endoscopic outcomes from AbbVie's maintenance trials for SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) in moderate to severe Crohn's disease and for RINVOQ in moderate to severe ulcerative colitis –   Primary efficacy and safety results from the Phase 3 INSPIRE induction study for risankizumab in ulcerative colitis will be presented –   A total of 23 abstracts, including a late-breaker, with 11 oral presentations, reinforce AbbVie's commitment to research into advancing standards of care for people living with inflammatory bowel diseases (IBD)  NORTH CHICAGO, Ill. , Oct. 10, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will share new data from its robust gastroenterology portfolio at the United European Gastroenterology (UEG) Week 2023 Congress taking place in Copenhagen, Denmark from October 14-17.

AbbVie Showcases Breadth and Depth of Research in Crohn's Disease and Ulcerative Colitis at UEG Week 2023

In the most recent trading session, AbbVie (ABBV) closed at $149.11, indicating a +0.59% shift from the previous trading day.

AbbVie (ABBV) Rises Yet Lags Behind Market: Some Facts Worth Knowing

Amgen

With bond yields near historic highs in many instances, stock prices have softened at the onset of Q4. Even so, dividend stocks are still likely to outperform most other asset classes in both the short and long terms.

2 Magnificent Dividend Stocks to Buy Hand Over Fist in October

AbbVie's (ABBV) buyout of Mitokinin, which is making a novel treatment for Parkinson's Disease (PD), if successfully closed, is likely to strengthen its neuroscience pipeline.

AbbVie (ABBV) Buys Parkinson's Disease Treatment Maker

AbbVie has an impressive streak of consecutive dividend increases. Its underlying business is solid despite one current challenge.

Should You Load Up On This 1 Dividend Stock?

Chevron

Coca-Cola

Dividend investing will always stay in style. While the market moves in cycles of ups and downs, dividend investing offers income even during prolonged market downturns.

Retirement Royalty: 3 Dividend Aristocrats for a Steady Income Stream

-  Mitokinin's lead compound, a selective PINK1 activator, is designed to address mitochondrial dysfunction, which plays a key role in the pathogenesis of Parkinson's disease -  Activation of PINK1 remediates mitochondrial damage and restores mitochondrial function NORTH CHICAGO, Ill. , Oct. 5, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has exercised its exclusive right and completed the acquisition of Mitokinin, a discovery-stage biotechnology company developing a potentially first-in-class disease-modifying treatment for Parkinson's Disease (PD).

AbbVie Exercises Exclusive Right to Acquire Mitokinin, Further Strengthening Neuroscience Pipeline

Cardinal Health

CVS Health

Johnson & Johnson

Medtronic

Patterson Companies

UnitedHealth Group

Facing an uncertain market environment, investors ought to consider the top healthcare stocks that pay dividends. Sure, the Federal Reserve may be in a position to facilitate a soft landing for the economy, per bullish analysts.

7 Top Healthcare Stocks That Pay Dividends

Accenture Plc

Automatic Data Processing

Applied Materials

ASML Hld

Best Buy

Blackrock Inc

Expeditors International of Washington

Fastenal

Ferguson Enterprises Inc

Garmin

Home Depot

Infosys

KLA-Tencor

Lockheed Martin

Lowe's

Lam Research

Mastercard

Monolithic Power Systems

Merck

Paychex

Rollins

Schwab US Dividend Equity ETF

Snap-on

Skyworks Solutions

T. Rowe Price Group

Taiwan Semiconductor Manufacturing

Texas Instruments

Visa

The 4-factor dividend growth portfolio is a strategy that leverages the stock selection process of Schwab U.S. Dividend Equity ETF, with a few minor twists. The portfolio fell by 6.29% in September, underperforming the S&P 500 by 1.53%. Year-to-date, the portfolio is up 6.89%. Since its inception, the portfolio has generated 1.90% of alpha over the S&P 500.

4 Factor Dividend Growth Portfolio: First Year Is Coming Down To The Wire

NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif.

Nature Publishes Discovery and Preclinical Results for ABBV-CLS-484, a Potential First-in-Class PTPN2/N1 Inhibitor in Cancer Immunotherapy

Comcast

McDonald's

AbbVie, McDonald's, and Comcast all provide investors with above-average yields. They have been increasing their payouts for years, and more increases are likely on the way.

3 High-Yielding Dividend Growth Stocks That Have Increased Their Payouts by 50% in 5 Years

NORTH CHICAGO, Ill. , Oct. 4, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its third-quarter 2023 financial results on Friday, October 27, 2023, before the market opens.

AbbVie to Host Third-Quarter 2023 Earnings Conference Call

Amphenol

Broadcom

Bank of New York Mellon

CBRE Group

Cigna

Elevance Health Inc

Eli Lilly

Microchip Technology

Mettler-Toledo

PPG Industries

Why settle for stocks limping to the finish line? Some investors found S&P 500 stocks that finish the year on a high note.

There's Still Time To Own 13 Stocks That Finish The Year Strong

News for AbbVie Stock (ABBV)